Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Small Cell Lung Cancer Key 1. Aged 18 to 75 years old of either gender; 2. A histopathological or cytological diagnosis of small cell lung cancer(SCLC); 3. Recurrence or progression disease after firstline platinum-containing chemotherapy and patients intolerant or unwilling to receive standard treatment; 4. Measurable cancer lesion according to Response Evaluation in Solid Tumors (RECIST) v1.1; 5. Eastern Cooperative Oncology Group(ECOG) performance status score 0-1; 6. Estimated life expectancy >4 months; 7. Taking drugs orally; 8. The function of important organs meets the following requirements: 1. white blood cell count (WBC) ≥ 4.0×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L, platelets ≥ 100×109/L, hemoglobin ≥ 90g/L; 2. ALT, AST and AKP ≤ 2.5×ULN; liver metastasis: ALT、AST≤ 5.0×ULN, ALP ≤ 6.0×ULN; bone metastases ALT、AST≤ 2.5×ULN, ALP ≤ 5.0×ULN; 3. serum albumin ≥ 30g/L; 4. total bilirubin ≤ 1.5×ULN; 5. serum creatinine ≤ 1.5×ULN, creatinine clearance rate ≥60 mL/min; 6. INR ≤ 1.5, PT≤ 1.5×ULN; 10. Serum HCG negative in premenopausal women, female patients of childbearing potential and male patients with female partners of childbearing potential must be willing to avoid pregnancy; 11. Ability to understand the study and sign informed consent. Key  Patients who have been treated previously for SCLC with two system chemotherapy (except for targeted therapy, immunotherapy and antiangiogenic therapy); 2. Patients who have been treated previously with topotecan, Irinotecan or other topoisomerase I inhibitors; 3. Known or suspected allergy or hypersensitivity to the investigational drug gimatecan ingredients or their analogues; 4. Other anticancer therapy including any investigational agent within 28 days prior to the first dose of the investigational drug gimatecan; 5. Patients who have been treated previously with intravenous or oral drugs that affect CYP isoenzymes within 7 days prior to the first dose of the investigational drug gimatecan; 6. Brain metastasis or meningeal metastasis (except for asymptomatic patients with lesion stable more than 28 days); 7. Major surgical intervention or trauma within 28 days prior to the first dose of investigational drug administration; 8. A history of gastrointestinal disease which affects drug absorption; 9. A history of allogeneic stem cell transplantation and organ transplantation; 10. A history of interstitial lung disease or non-infectious pneumonia; 11. Patients who cannot tolerate chemotherapy due to severe cardiac, lung, liver or kidney dysfunction, or hematopoietic disease or cachexia; 12. A history of immunodeficiency (including a positive HIV test result), or other acquired or congenital immunodeficiency diseases; 13. Presence of active hepatitis B (HBV DNA ≥ 200 IU/mL or 103 copies/mL), hepatitis C (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay); 14. A history of active pulmonary tuberculosis infection within 1 year or a history of active pulmonary tuberculosis infection more than 1 year ago but without formal anti-tuberculosis treatment; 15. A history of malignancies other than esophageal cancer before enrollment, excluding non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer; 16. Pregnant or lactating women